Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Afatinib dimaleate by Boehringer Ingelheim International for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval
Afatinib dimaleate is under clinical development by Boehringer Ingelheim International and currently in Phase I for Bile Duct Cancer (Cholangiocarcinoma)....
Data Insights
Afatinib dimaleate by Boehringer Ingelheim International for Refractory Multiple Myeloma: Likelihood of Approval
Afatinib dimaleate is under clinical development by Boehringer Ingelheim International and currently in Phase II for Refractory Multiple Myeloma. According...